HtrA2 (OMI) Antibody (C-term) Blocking Peptide
€363.00
In stock
SKU
AC-BP1333b
Background:
Insulin-like growth factors (IGFs) stimulate the proliferation and differentiation of a vast number of cell types. The action of the growth factors is mediated and controlled by a complex system of components, including several proteases that cleave the IGF-Binding Proteins. HtrA1 is a 480 aa protein that contains an N-terminus homologous to MAC25 (IGFBP7) with a conserved Kazal-type serine protease inhibitor motif, as well as a C-terminal PDZ domain. Semiquantitative RT-PCR and immunoblot analyses showed an approximately 7-fold increase of PRSS11 in osteoarthritis cartilage compared with controls. HTRA2 is released from mitochondria and inhibits the function of XIAP by direct binding in a way similar to SMAC. Moreover, when overexpressed extramitochondrially, HTRA2 induced atypical cell death, which was neither accompanied by a significant increase in caspase activity nor inhibited by caspase inhibitors, including XIAP. A catalytically inactive mutant of HTRA2, however, did not induce cell death. Suzuki et al. (2001) concluded that HTRA2 is a SMAC-like inhibitor of IAP (inhibitor of apoptosis proteins) activity with a serine protease-dependent cell death-inducing activity.
Other Names:
Serine protease HTRA2, mitochondrial, High temperature requirement protein A2, HtrA2, Omi stress-regulated endoprotease, Serine protease 25, Serine proteinase OMI, HTRA2, OMI, PRSS25
Target/Specificity:
The synthetic peptide sequence used to generate the antibody AP1333b was selected from the OMI region of human HtrA2 (OMI). A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.
Gene Name: HTRA2
Gene ID: 27429
Primary Accession: O43464
Other Accession: NP_659540
Format: Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.
Insulin-like growth factors (IGFs) stimulate the proliferation and differentiation of a vast number of cell types. The action of the growth factors is mediated and controlled by a complex system of components, including several proteases that cleave the IGF-Binding Proteins. HtrA1 is a 480 aa protein that contains an N-terminus homologous to MAC25 (IGFBP7) with a conserved Kazal-type serine protease inhibitor motif, as well as a C-terminal PDZ domain. Semiquantitative RT-PCR and immunoblot analyses showed an approximately 7-fold increase of PRSS11 in osteoarthritis cartilage compared with controls. HTRA2 is released from mitochondria and inhibits the function of XIAP by direct binding in a way similar to SMAC. Moreover, when overexpressed extramitochondrially, HTRA2 induced atypical cell death, which was neither accompanied by a significant increase in caspase activity nor inhibited by caspase inhibitors, including XIAP. A catalytically inactive mutant of HTRA2, however, did not induce cell death. Suzuki et al. (2001) concluded that HTRA2 is a SMAC-like inhibitor of IAP (inhibitor of apoptosis proteins) activity with a serine protease-dependent cell death-inducing activity.
Other Names:
Serine protease HTRA2, mitochondrial, High temperature requirement protein A2, HtrA2, Omi stress-regulated endoprotease, Serine protease 25, Serine proteinase OMI, HTRA2, OMI, PRSS25
Target/Specificity:
The synthetic peptide sequence used to generate the antibody AP1333b was selected from the OMI region of human HtrA2 (OMI). A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.
Gene Name: HTRA2
Gene ID: 27429
Primary Accession: O43464
Other Accession: NP_659540
Format: Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.
| Is Featured? | No |
|---|
Write Your Own Review